BMS Reports the Updated Data from P-III (CheckMate -73L) Study of Opdivo for Non-Small Cell Lung Cancer
Shots:
- The P-III (CheckMate -73L) study compares Opdivo + concurrent chemoradiotherapy (CCRT) followed by Opdivo + Yervoy (Arm A) or Opdivo alone (Arm B) to CCRT alone followed by durvalumab (Arm C) in treatment-naïve unresectable locally advanced stage III NSCLC patients (n=925)
- The 1EP of the study includes PFS for Arm A vs Arm C while the 2EPs include OS, PFS, ORR, TTR, DoR, and further safety & effectiveness
- The study did not reach the 1EP of PFS and the AEs across Arm A were consistent. The full evaluation of the study continues and the data will be presented to the scientific community
Ref: BMS | Image: BMS
Related News:- BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
